“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > ORGANIZATION
ORGANIZATION
- 4.5 Bil. Yen Tax Hike Estimated in FY2012 Tax Reform: JPMA
July 17, 2012
- Wholesaler FTC to Make Serious Efforts for Improving “Services of Convenience”
July 13, 2012
- Japan Should Not Copy Foreign HTA Systems: Mr Grainger of PhRMA
July 12, 2012
- JMA Asks Sanofi Pasteur to Lower Price for Inactivated Polio Vaccine
July 9, 2012
- 60% of Respondents Are Unaware That Colorectal Cancer is Asymptomatic Ill: Survey
July 9, 2012
- OPIR Says Surplus of Drug Imports “Unrelated to International Competitiveness of Domestic Industry”
July 6, 2012
- JPMA Calls for Restoration of 30% Maximum Deduction Rate in R&D Tax Credit System
July 4, 2012
- 30% of Medical Institutions Introduce Generic Name Prescribing: Yakukeiren Survey
July 3, 2012
- JGA Begins Posting Information on Out-of-Stock Products, Delayed Shipments on Website
July 3, 2012
- JPA Vice President Miura Calls for Discussions on Role of Pharmacies; Raises Question about Dividends Paid by Listed Pharmacies
June 27, 2012
- Legal Prescription Receipt Rate at Record-High 64.6% in FY2011: JPA
June 26, 2012
- JPWA, NPhA Confirm Need for Thorough Efforts “at Ground Level” for Distribution Improvements
June 25, 2012
- Products from 2nd Round of Development Requests Now Eligible for PDSC Subsidies
June 19, 2012
- Astellas’ Nogimori New Acting President of IFPMA
June 18, 2012
- NPhA Survey: Nearly Half of Pharmacy Operators Have Received No Price Offers from Wholesalers
June 18, 2012
- Generic Market Share Increases Marginally to 23.3% in FY2011: JGA
June 18, 2012
- Drugs Developed in Response to Gov’t Request Should Be Exempted from Downward Foreign Average Price Adjustment: FPMAJ
June 13, 2012
- 48 Products Subjected to Market Expansion Re-Pricing in FY2012: FPMAJ Survey
June 13, 2012
- Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ
June 12, 2012
- FPMAJ’s Subcommittee Calls for Discussion on Need for “Ad Hoc Price Reduction” for Long-Listed Drugs
June 12, 2012
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…